Applied Finance Capital Management LLC Has $16.76 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Applied Finance Capital Management LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 31,566 shares of the medical research company's stock after acquiring an additional 3,297 shares during the quarter. Applied Finance Capital Management LLC's holdings in Thermo Fisher Scientific were worth $16,755,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Allworth Financial LP increased its position in shares of Thermo Fisher Scientific by 14.3% in the 3rd quarter. Allworth Financial LP now owns 2,344 shares of the medical research company's stock valued at $1,187,000 after purchasing an additional 293 shares during the last quarter. Wealthfront Advisers LLC grew its position in shares of Thermo Fisher Scientific by 4.0% in the 3rd quarter. Wealthfront Advisers LLC now owns 21,212 shares of the medical research company's stock valued at $10,737,000 after buying an additional 817 shares during the last quarter. Wisconsin Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $276,000. Baron Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 13.8% in the 3rd quarter. Baron Wealth Management LLC now owns 1,083 shares of the medical research company's stock valued at $548,000 after buying an additional 131 shares during the last quarter. Finally, Centerpoint Advisors LLC grew its position in shares of Thermo Fisher Scientific by 7.0% in the 3rd quarter. Centerpoint Advisors LLC now owns 2,669 shares of the medical research company's stock valued at $1,351,000 after buying an additional 175 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.3 %

Shares of NYSE TMO traded down $1.85 during midday trading on Friday, reaching $595.30. 1,398,449 shares of the stock were exchanged, compared to its average volume of 1,463,725. The company has a market capitalization of $227.24 billion, a P/E ratio of 38.18, a P/E/G ratio of 2.47 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The stock has a 50 day moving average price of $576.74 and a 200-day moving average price of $542.69.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's payout ratio is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company's stock, valued at $7,430,359.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,000 shares of company stock valued at $18,486,980. Corporate insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on TMO shares. Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research report on Thursday, April 25th. Finally, Barclays raised their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.